Newsfile (Mon, 13-Apr 7:00 AM ET)
Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026
Newsfile (Thu, 9-Apr 7:00 AM ET)
Newsfile (Mon, 30-Mar 7:01 AM ET)
Newsfile (Mon, 23-Mar 7:00 AM ET)
Newsfile (Mon, 16-Mar 11:31 AM ET)
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Globe Newswire (Fri, 13-Mar 8:35 AM ET)
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
Globe Newswire (Tue, 10-Mar 10:21 AM ET)
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT
Globe Newswire (Tue, 10-Mar 7:59 AM ET)
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT
Newsfile (Tue, 10-Mar 7:01 AM ET)
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update
Newsfile (Thu, 5-Mar 4:06 PM ET)
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
Phio Pharmaceuticals Corp. trades on the NASDAQ stock market under the symbol PHIO.
As of April 22, 2026, PHIO stock price was flat at $1.25 with 27,729 million shares trading.
PHIO has a beta of 0.09, meaning it tends to be less sensitive to market movements. PHIO has a correlation of 0.00 to the broad based SPY ETF.
PHIO has a market cap of $14.52 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, PHIO traded as high as $61.65 and as low as $.81.
The top ETF exchange traded funds that PHIO belongs to (by Net Assets): VXF.
PHIO has underperformed the market in the last year with a price return of -55.8% while the SPY ETF gained +39.5%. However, in the short term, PHIO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +20.2% vs +3.8% return in SPY. But in the last 2 weeks, PHIO shares have been beat by the market, returning +0.8% compared to an SPY return of +7.6%.
PHIO support price is $1.20 and resistance is $1.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHIO shares will trade within this expected range on the day.